Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy

Figure 4 Response-guided therapy strategy for predicting response at 24 wk post-treatment based on hepatitis B surface antigen and hepatitis B e antigen levels at baseline, week 12, and week 24 in the management of previously treated patients with hepatitis B e antigen-positive chronic hepatitis B. ¹According to the prediction models, patients who didn’t meet the two cutoffs at baseline had a response of 23.8% at end of follow-up. So we gave a recommendation of slightly considering peginterferon-alfa. ²For patients who didn’t meet corresponding two cutoffs at week 12 or week 24 but met cutoffs at baseline, peginterferon-alfa could be considered because there was a possibility of attaining a response at end of follow-up. CHB: Chronic hepatitis; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; PEG-IFNα: Peginterferon-alfa.